Literature DB >> 18392021

Targeting siRNA to arrest fibrosis.

Scott L Friedman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18392021     DOI： 10.1038/nbt0408-399

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  5 in total

Review 1.  Evolving challenges in hepatic fibrosis.

Authors:  Scott L Friedman
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-06-29       Impact factor: 46.802

Review 2.  Hepatic fibrosis.

Authors:  Jingjing Jiao; Scott L Friedman; Costica Aloman
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

3.  Strategies for blocking the fibrogenic actions of connective tissue growth factor (CCN2): From pharmacological inhibition in vitro to targeted siRNA therapy in vivo.

Authors:  David R Brigstock
Journal:  J Cell Commun Signal       Date:  2009-03-18       Impact factor: 5.782

Review 4.  Development of nonalcoholic hepatopathy: contributions of oxidative stress and advanced glycation end products.

Authors:  Juliana Célia de F Santos; Iara B Valentim; Orlando R P de Araújo; Terezinha da R Ataide; Marília O F Goulart
Journal:  Int J Mol Sci       Date:  2013-10-01       Impact factor: 5.923

5.  BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial.

Authors:  Eric J Lawitz; Diane E Shevell; Giridhar S Tirucherai; Shuyan Du; Warner Chen; Uma Kavita; Angie Coste; Fred Poordad; Morten Karsdal; Mette Nielsen; Zachary Goodman; Edgar D Charles
Journal:  Hepatology       Date:  2021-12-13       Impact factor: 17.298
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.